DK3009426T3 - 4-alkynyl-imidazol-derivat og lægemiddel omfattende samme som aktiv bestanddel - Google Patents

4-alkynyl-imidazol-derivat og lægemiddel omfattende samme som aktiv bestanddel Download PDF

Info

Publication number
DK3009426T3
DK3009426T3 DK14811154.5T DK14811154T DK3009426T3 DK 3009426 T3 DK3009426 T3 DK 3009426T3 DK 14811154 T DK14811154 T DK 14811154T DK 3009426 T3 DK3009426 T3 DK 3009426T3
Authority
DK
Denmark
Prior art keywords
group
mmol
compound
methyl
added
Prior art date
Application number
DK14811154.5T
Other languages
English (en)
Inventor
Satoru Ikegami
Atsushi Watanabe
Kimio Hirano
Tadashi Ohyama
Original Assignee
Kaken Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd filed Critical Kaken Pharma Co Ltd
Application granted granted Critical
Publication of DK3009426T3 publication Critical patent/DK3009426T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (17)

1. 4-alkynylimidazolderivat med den generelle formel (I) eller et farmaceutisk acceptabelt salt deraf: [Formel 1]
[hvor ring A er en cyclohexyl substitueret med E i 4-stillingen eller en phenyl substitueret med E i 4-stillingen; ring B er cycloalkyl, aryl eller heteroaryl; m er et helt tal af en hvilken som helst af 0~2; n er et helt tal af en hvilken som helst af 1~3; R1 er et hydrogenatom, en Ci~C4-alkylgruppe, en Ci~C4-alkoxygruppe, et halogenatom eller en Ci~C4-halogenalkylgruppe; R2 og R3 er hver uafhængigt et hydrogenatom, et halogenatom eller en Ci~C4-alkylgruppe eller kan sammen med det carbonatom, hvortil R2 og R3 støder op til hinanden, danne en C3~C6-carbonring; R4 og R5 er hver uafhængigt et hydrogenatom eller en Ci~C4-alkylgruppe eller kan sammen med det carbonatom, hvortil R4 og R5 støder op til hinanden, danne en C3~C6-carbonring, og R5 og R7 hver uafhængigt er et hydrogenatom, en Ci~C4-alkylgruppe, en Ci~C4-alkoxygruppe, en Ci~C4-hydroxyalkylgruppe, en carboxylgruppe, en cyanogruppe, et halogenatom, en Ci~C4-halogenalkylgruppe, eller en Ci~C4-halogenalkoxygruppe; X er -OR8, -NR9R10 eller et halogenatom; R8 er et hydrogenatom, en Ci~C4-alkylgruppe eller en Ci~C4-halogenalkylgruppe; R9 og R10 er hver uafhængigt et hydrogenatom eller en Ci~C4-alkylgruppe eller kan, sammen med nitrogenatomet, hvortil R9 og R10 støder op til hinanden, danne en nitrogen-holdig heterocyklisk gruppe, Y er en enkeltbinding, et oxygenatom eller et svovlatom; og E er -CO2H, -CO2P, hvor P repræsenterer alkyl, proxetil eller medoxomil eller en bioi-soster af en carboxylgruppe repræsenteret ved hydroxamsyre (-CO-NH-OH), sulfonamid (-NH-S02-Ci~C6-alkyl), acylcyanamid (-CO-NH-CN), acylsulfonamid (-C0-NH-S02-Ci~C6-alkyl, -S02-NH-C0-Ci~C6-alkyl), tetrazolyl, oxadiazolonyl, oxadiazolthionyl, oxathiadi-azolyl, thiadiazolonyl, triazolthionyl og hydroxyisoxazolyl].
2. 4-alkynylimidazolderivat ifølge krav 1 eller et farmaceutisk acceptabelt salt deraf, hvor i den foregående generelle formel (I) X er -OR8 (R8 er som defineret i krav 1), og m er 0.
3.
4-alkynylimidazolderivat ifølge krav 1 eller 2 eller et farmaceutisk acceptabelt salt deraf, hvor R2 og R3 i den foregående generelle formel (I) begge er en methylgruppe. 4. 4-alkynylimidazolderivat ifølge et hvilket som helst af kravene 1 til 3 eller et farmaceutisk acceptabelt salt deraf, hvor R1 i den foregående generelle formel (I) er en methylgruppe, en ethylgruppe, en cyclopropylgruppe, et chloratom, en difluormethylgrup-pe eller en trifluormethylgruppe.
5. 4-alkynylimidazolderivat ifølge krav 4 eller et farmaceutisk acceptabelt salt deraf, hvor R1 i det foregående almene formel (I) er et chloratom.
6. 4-alkynylimidazolderivat ifølge et hvilket som helst af kravene 1 til 5 eller et farmaceutisk acceptabelt salt deraf, hvor E i den foregående formel (I) er -CO2H eller tetra-zolyl.
7. 4-alkynylimidazolderivat ifølge et hvilket som helst af kravene 1 til 6 eller et farmaceutisk acceptabelt salt deraf, hvor i den foregående formel (I) ring B er phenyl, n er 1, og Y er en enkeltbinding.
8. 4-alkynylimidazolderivat ifølge krav 7 eller et farmaceutisk acceptabelt salt deraf, hvor i den foregående formel (I) ring B er phenyl substitueret med R5 i 4-stillingen, R7 er et hydrogenatom, og R5 er enhver en af en Ci~C4-alkylgruppe, en Ci~C4-alkoxygruppe, en cyanogruppe, et halogenatom, en Ci~C4-halogenalkylgruppe og en Ci~C4-halogenalkoxygruppe.
9. 4-alkynylimidazolderivat ifølge krav 1 eller et farmaceutisk acceptabelt salt deraf, hvor forbindelsen repræsenteret ved den foregående formel (I) er en hvilken som helst af:
10. 4-alkynylimidazolderivat ifølge krav 9 eller et farmaceutisk acceptabelt salt deraf, hvor forbindelsen repræsenteret ved den foregående formel (I) er: [Formel 3]
11. Farmaceutisk middel omfattende 4-alkynylimidazolderivatet ifølge et hvilket som helst af kravene 1 til 10 eller et farmaceutisk acceptabelt salt deraf som en aktiv bestanddel.
12. EP4-receptorantagonist omfattende 4-alkynylimidazolderivatet ifølge et hvilket som helst af kravene 1 til 10 eller et farmaceutisk acceptabelt salt deraf.
13. Farmaceutisk middel som defineret i krav 11 til anvendelse til behandling af en inflammatorisk sygdom eller en inflammatorisk smerte.
14. Farmaceutisk middel til anvendelse ifølge krav 13, hvor den inflammatoriske sygdom eller inflammatoriske smerte er mindst én valgt fra gruppen bestående af arthri-tisk smerte, artikulær reumatisme, slidgigt, lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrom, tendonitis og thecitis.
15. Farmaceutisk middel til anvendelse ifølge krav 13 eller 14, hvor behandlingen er antiinflammation og/eller smertelindring.
16. Farmaceutisk middel som defineret i krav 11 til anvendelse ved behandlingen af mindst én sygdom valgt fra gruppen bestående af multipel sklerose, ulcerativ colitis, Crohns sygdom, atopisk dermatitis, psoriasis og kontaktdermatitis.
17. Farmaceutisk middel til anvendelse ifølge krav 16, hvor sygdommen er multipel sklerose.
DK14811154.5T 2013-06-12 2014-06-12 4-alkynyl-imidazol-derivat og lægemiddel omfattende samme som aktiv bestanddel DK3009426T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013123968 2013-06-12
PCT/JP2014/065643 WO2014200075A1 (ja) 2013-06-12 2014-06-12 ４－アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬

Publications (1)

Publication Number Publication Date
DK3009426T3 true DK3009426T3 (da) 2018-05-28

Family

ID=52022361

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14811154.5T DK3009426T3 (da) 2013-06-12 2014-06-12 4-alkynyl-imidazol-derivat og lægemiddel omfattende samme som aktiv bestanddel

Country Status (29)

Country Link
US (2) US9593081B2 (da)
EP (1) EP3009426B1 (da)
JP (1) JP6276760B2 (da)
KR (1) KR102212981B1 (da)
CN (1) CN105431416B (da)
AU (1) AU2014279113B2 (da)
BR (1) BR112015030315B1 (da)
CA (1) CA2914997C (da)
DK (1) DK3009426T3 (da)
ES (1) ES2669977T3 (da)
HK (1) HK1221215A1 (da)
HR (1) HRP20180703T1 (da)
HU (1) HUE039015T2 (da)
IL (1) IL242912A0 (da)
LT (1) LT3009426T (da)
MX (1) MX369804B (da)
MY (1) MY168609A (da)
NO (1) NO3009426T3 (da)
NZ (1) NZ715837A (da)
PH (1) PH12015502745A1 (da)
PL (1) PL3009426T3 (da)
PT (1) PT3009426T (da)
RS (1) RS57406B1 (da)
RU (1) RU2662806C2 (da)
SG (1) SG11201510121RA (da)
SI (1) SI3009426T1 (da)
TR (1) TR201807659T4 (da)
WO (1) WO2014200075A1 (da)
ZA (1) ZA201600135B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9593081B2 (en) * 2013-06-12 2017-03-14 Kaken Pharmaceutical Co., Ltd. 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
BR112019009801A2 (pt) * 2016-11-18 2019-08-06 Dow Agrosciences Llc 4-((6-(2-(2,4-difluorofenil)-1,1-difluoro-2-hidróxi-3-(5-mercapto-1h-1,2,4-triazol-1-il)propil)piridin-3-il)óxi)benzonitrila e processos de preparação
EP3625228B1 (en) 2017-05-18 2021-07-07 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as pge2 receptor modulators
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
CN110621667A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 嘧啶衍生物
WO2018210994A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators
RS62441B1 (sr) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd N-supstituisani derivati indola
TW201900613A (zh) 2017-05-22 2019-01-01 日商小野藥品工業股份有限公司 Ep 拮抗劑
JP2020142989A (ja) * 2017-06-21 2020-09-10 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 イミダゾール誘導体及びそれを含有する医薬
WO2019149286A1 (en) * 2018-02-05 2019-08-08 Shenzhen Ionova Life Science Co., Ltd. Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases
CN108997252B (zh) * 2018-07-27 2020-04-28 常州大学 一种恶二唑衍生物的绿色合成方法
TW202228674A (zh) 2020-11-13 2022-08-01 日商小野藥品工業股份有限公司 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12542A (en) * 2001-01-31 2006-06-05 Pfizer Prod Inc Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4isozymes.
RU2315746C2 (ru) * 2001-08-09 2008-01-27 Оно Фармасьютикал Ко., Лтд. Производные карбоновых кислот и фармацевтическое средство, содержащее их в качестве активного ингредиента
BR0311247A (pt) 2002-05-23 2005-03-15 Theratechnologies Inc Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2
EP1663979B1 (en) 2003-09-03 2013-10-09 RaQualia Pharma Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
ES2327760T3 (es) 2004-05-04 2009-11-03 Raqualia Pharma Inc Compuestos de aril-heteroaril-amida ortosustituidos.
MXPA06011555A (es) 2004-05-04 2006-12-15 Pfizer Compuestos de metil-aril o heteroaril-amida sustituida.
WO2006087355A1 (en) * 2005-02-16 2006-08-24 Solvay Pharmaceuticals B.V. 1h-imidiazole derivatives as cannabinoid cb2 receptor modulators
ES2392192T3 (es) 2006-04-24 2012-12-05 Merck Canada Inc. Derivados de indol amida como antagonistas del receptor EP4
WO2007143825A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
CA2660133C (en) 2006-08-11 2015-10-27 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
US8158671B2 (en) * 2007-02-26 2012-04-17 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
JP5431316B2 (ja) * 2007-07-02 2014-03-05 エフ．ホフマン−ラ ロシュ アーゲー Ｃｃｒ２受容体アンタゴニストとしてのイミダゾール誘導体
WO2009005076A1 (ja) 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
PT2565191E (pt) 2008-05-14 2014-12-04 Astellas Pharma Inc Derivados do ácido 4-(indol-7- ilcarbonilaminometil)ciclo-hexanocarboxílico como antagonistas de receptores ep4, úteis no tratamento de insuficiência renal crónica ou de nefropatia diabética
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
CN103097358B (zh) * 2010-09-21 2015-04-08 卫材R&D管理有限公司 药物组合物
EP2649061B1 (en) 2010-12-10 2015-05-13 Rottapharm Biotech S.r.l. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
ES2559513T3 (es) 2011-07-04 2016-02-12 Rottapharm Biotech S.R.L. Derivados de amina cíclica como antagonistas del receptor EP4
US9593081B2 (en) * 2013-06-12 2017-03-14 Kaken Pharmaceutical Co., Ltd. 4-alkynyl imidazole derivative and medicine comprising same as active ingredient

Also Published As

Publication number Publication date
US20160130232A1 (en) 2016-05-12
SI3009426T1 (en) 2018-06-29
MX2015017161A (es) 2016-04-06
CA2914997A1 (en) 2014-12-18
PH12015502745B1 (en) 2016-03-14
US9593081B2 (en) 2017-03-14
PT3009426T (pt) 2018-06-08
CN105431416B (zh) 2019-01-08
TR201807659T4 (tr) 2018-06-21
CA2914997C (en) 2021-07-20
MY168609A (en) 2018-11-14
SG11201510121RA (en) 2016-01-28
CN105431416A (zh) 2016-03-23
EP3009426B1 (en) 2018-05-02
ZA201600135B (en) 2017-04-26
AU2014279113A1 (en) 2016-01-21
NZ715837A (en) 2020-01-31
US20170128431A1 (en) 2017-05-11
HRP20180703T1 (hr) 2018-06-15
RS57406B1 (sr) 2018-09-28
RU2662806C2 (ru) 2018-07-31
HUE039015T2 (hu) 2018-12-28
RU2015155585A (ru) 2017-07-17
LT3009426T (lt) 2018-07-25
BR112015030315A2 (pt) 2017-07-25
JPWO2014200075A1 (ja) 2017-02-23
KR20160018745A (ko) 2016-02-17
NO3009426T3 (da) 2018-09-29
EP3009426A1 (en) 2016-04-20
HK1221215A1 (zh) 2017-05-26
ES2669977T3 (es) 2018-05-29
EP3009426A4 (en) 2016-10-19
WO2014200075A1 (ja) 2014-12-18
US9855257B2 (en) 2018-01-02
JP6276760B2 (ja) 2018-02-07
PH12015502745A1 (en) 2016-03-14
MX369804B (es) 2019-11-21
BR112015030315B1 (pt) 2022-10-04
AU2014279113B2 (en) 2018-04-12
PL3009426T3 (pl) 2018-09-28
IL242912A0 (en) 2016-02-01
KR102212981B1 (ko) 2021-02-04

Similar Documents

Publication Publication Date Title
DK3009426T3 (da) 4-alkynyl-imidazol-derivat og lægemiddel omfattende samme som aktiv bestanddel
RU2518073C2 (ru) Новое бициклическое гетероциклическое соединение
JP6918819B2 (ja) オルトミクソウイルス感染の処置に有用な三環式化合物
CA2896554C (en) Novel antiviral agents against hbv infection
KR102093608B1 (ko) 이미다조피리딘 화합물
KR100862879B1 (ko) Ｈｉｖ 인테그라제의 ｎ-치환된 하이드록시피리미디논 카복스아미드 억제제
JP4602672B2 (ja) プロスタグランジンｆ受容体のモジュレーターとしてのチアゾリジンカルボキサミド誘導体
WO2014181287A1 (en) Heterocyclyl compounds and uses thereof
MX2014015350A (es) Compuestos de triazolona como inhibidores de mpegs-1.
TW200843744A (en) Dual-acting antihypertensive agents
AU2015281021B9 (en) Salt of halogen-substituted heterocyclic compound
WO2010111059A1 (en) P2x3 receptor antagonists for treatment of pain
CA2870336A1 (en) Cyclic bridgehead ether dgat1 inhibitors
WO2012036278A1 (ja) グリシントランスポーター阻害物質
EP3334727A1 (en) Pyridine and pyrimidine derivatives
TW201245187A (en) Pyrazole derivatives
CA2992698A1 (en) Nitrogen-containing heterocyclic compound
CA3233410A1 (en) Benzimidazoles as modulators of il-17
JP2023552655A (ja) ボロン酸化合物
KR20200022710A (ko) Ｔ-형 칼슘 채널에 활성을 가지는 피롤리딘 또는 피페리딘 화합물
WO2019022234A1 (ja) 炎症性腸疾患の治療剤又は予防剤
ITRM20150070A1 (it) Human helicase ddx3 inhibitors as therapeutic agents